Please check your internet connection and try again.
# Mylotarg (gemtuzumab ozogamicin)
## Overview
Mylotarg is a humanized monoclonal antibody conjugated to an antibiotic (calicheamicin). It targets CD33, a surface antigen found on myeloid leukemia cells. Upon binding to CD33, it is internalized, releasing its cytotoxic agent and leading to DNA damage and cell death.
## Primary Indications
Mylotarg is indicated for the treatment of:
* Newly diagnosed acute myeloid leukemia (AML) in adult patients in combination with other chemotherapy.
* Relapsed or refractory AML in adult patients.
## Adult Dosing
The dosing regimen for Mylotarg can be complex and depends on the specific indication and whether it is used in combination or as monotherapy. Regimens often involve multiple doses.
**For newly diagnosed AML (in combination with chemotherapy):**
* **First cycle:** 3 mg/m² on days 1, 4, and 7.
* **Second cycle (if applicable):** 3 mg/m² on day 1.
**For relapsed or refractory AML (as monotherapy):**
* **First cycle:** 3 mg/m² on day 1. If tolerated, subsequent doses of 3 mg/m² can be administered on days 4 and 7.
* **Subsequent cycles (if applicable):** 3 mg/m² every 2 weeks.
**Maximum cumulative dose:** Generally, a maximum cumulative dose of 10 mg/m² is recommended due to potential hepatotoxicity.
**Note:** Specific timing and frequency may vary based on chemotherapy backbone and clinical trial protocols. Always refer to the most current prescribing information or institutional guidelines.
## Pediatric Dosing
Mylotarg is **not approved** for use in pediatric patients. Safety and efficacy have not been established.
## Dose Adjustments
Dose modifications may be necessary due to adverse events, particularly:
* **Hepatotoxicity:** Dose interruption or discontinuation is required based on the severity of liver enzyme elevations or bilirubin increases.
* **Myelosuppression:** While expected, severe or prolonged myelosuppression may necessitate dose delays or reductions, especially in combination regimens.
## Contraindications
* None absolute, but caution is advised in patients with severe hepatic impairment.
## Adverse Effects
The most common adverse effects include:
* **Hematologic:** Thrombocytopenia, neutropenia, leukopenia, anemia.
* **Hepatic:** Hyperbilirubinemia, elevated AST/ALT.
* **Gastrointestinal:** Nausea, vomiting, diarrhea, stomatitis.
* **Infections:** Sepsis, pneumonia.
* **Other:** Fever, fatigue, rash, headache, mucositis.
**Black Box Warnings:**
* **Hepatotoxicity:** Severe, potentially fatal liver toxicity, including sinusoidal obstruction syndrome (SOS)/veno-occlusive disease (VOD), has occurred, especially in patients receiving Mylotarg concurrently with other chemotherapy agents or those with a history of hepatic impairment.
* **Hemorrhagic events:** Fatal and serious bleeding events have occurred.
## Key Drug Interactions
* **Hepatotoxic agents:** Concurrent use with other drugs known to cause hepatotoxicity may increase the risk of liver injury.
* **Myelosuppressive agents:** Mylotarg is inherently myelosuppressive and will exacerbate the myelosuppression caused by other chemotherapy agents.
## Monitoring
* **Complete Blood Count (CBC) with differential and platelets:** Frequently monitor for myelosuppression and bleeding risk.
* **Liver Function Tests (LFTs):** Monitor bilirubin, AST, ALT, and alkaline phosphatase regularly, especially before and during treatment.
* **Signs and symptoms of SOS/VOD:** Monitor for jaundice, ascites, hepatomegaly, and right upper quadrant pain.
* **Signs and symptoms of bleeding:** Monitor for petechiae, bruising, epistaxis, hematuria, and melena.
* **Renal function:** Monitor BUN and creatinine.
## Clinical Pearls
* Mylotarg carries significant risks of hepatotoxicity and hemorrhagic events, requiring close monitoring and careful patient selection.
* The risk of SOS/VOD is increased with concurrent chemotherapy.
* Consider prophylaxis for tumor lysis syndrome and infections.
* Ensure adequate hydration and supportive care for nausea/vomiting and diarrhea.
* Dose adjustments or interruptions are crucial for managing toxicity.
***
*Disclaimer: This information is intended for clinical professionals and is not a substitute for professional medical advice. Always verify current prescribing information and consult with your institution's guidelines before making any treatment decisions.*
